Ryvu Therapeutics S.A. (WSE:RVU)

Ryvu Therapeutics Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	49.7	59.61	160.07	57.94	101.92	83.24
Short-Term Investments	33.41	48.07	65.86	175.73	0.53	4.99
Cash & Short-Term Investments	83.11	107.68	225.93	233.67	102.45	88.23
Cash Growth	-54.36%	-52.34%	-3.31%	128.09%	16.11%	-45.26%
Accounts Receivable	11.04	10.6	15.66	9.19	1.05	5.94
Other Receivables	11.4	9.5	20.12	23.65	258.85	5.8
Receivables	22.45	20.1	35.78	32.84	259.89	11.74
Inventory	1.34	1.34	1.21	2.12	1.76	1.96
Prepaid Expenses	-	-	-	-	2.35	1.63
Other Current Assets	9.99	10.14	9.52	9.77	1.48	0.69
Total Current Assets	116.88	139.25	272.44	278.39	367.93	104.25
Property, Plant & Equipment	68.27	70.02	72.74	77.56	82.22	91.18
Long-Term Investments	6.62	6.38	16.77	34.37	20.48	29.4
Other Intangible Assets	6.31	6.04	8.12	6.34	4.28	3.04
Long-Term Deferred Tax Assets	-	-	-	-	-	0.33
Other Long-Term Assets	2.88	2.75	8.72	6.55	0.08	0.6
Total Assets	200.96	224.44	378.78	403.2	474.98	228.81

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	14.62	16.23	31.15	23.14	12.58	11.69
Accrued Expenses	2.34	3.74	12.28	12.22	11.7	4.86
Short-Term Debt	0.04	0.11	0.29	0.13	0.06	0.02
Current Portion of Long-Term Debt	13.97	16.08	25.79	-	0.81	0.81
Current Portion of Leases	0.35	0.38	0.5	0.41	1.03	1.92
Current Income Taxes Payable	-	-	-	-	-	5.46
Current Unearned Revenue	20.42	23.19	35.71	31.53	16.71	8.95
Other Current Liabilities	0	1.86	2.21	2.27	1.93	2.5
Total Current Liabilities	51.73	61.58	107.93	69.7	44.81	36.2
Long-Term Debt	80.8	78.38	74.15	8.85	9.9	8.86
Long-Term Leases	0.87	0.96	1.39	0.37	0.87	1.58
Long-Term Unearned Revenue	26.05	29.5	42.74	64.26	75.8	20.26
Pension & Post-Retirement Benefits	0.18	0.18	0.28	0.43	0.14	0.12
Long-Term Deferred Tax Liabilities	-	-	-	-	-	0.44
Other Long-Term Liabilities	-	-	-	-	0.06	0.06
Total Liabilities	159.63	170.6	226.48	143.61	131.59	67.51

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	9.25	9.25	9.25	9.25	7.34	7.34
Additional Paid-In Capital	519.75	519.75	519.75	519.75	279.06	279.06
Retained Earnings	-225.32	-212.67	-111.44	-0.01	92.1	175.88
Comprehensive Income & Other	-262.35	-262.49	-265.26	-269.39	-35.12	-300.99
Total Common Equity	41.33	53.83	152.29	259.59	343.39	161.3
Shareholders' Equity	41.33	53.83	152.29	259.59	343.39	161.3
Total Liabilities & Equity	200.96	224.44	378.78	403.2	474.98	228.81

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	96.03	95.9	102.12	9.76	12.67	13.19
Net Cash (Debt)	-12.93	11.78	123.81	223.91	89.77	75.04
Net Cash Growth	-	-90.49%	-44.71%	149.42%	19.63%	-51.20%
Net Cash Per Share	-0.56	0.51	5.36	9.78	4.89	4.09
Filing Date Shares Outstanding	23.12	23.12	23.12	23.12	23.12	18.36
Total Common Shares Outstanding	23.12	23.12	23.12	23.12	23.12	18.36
Working Capital	65.15	77.67	164.51	208.69	323.12	68.05
Book Value Per Share	1.79	2.33	6.59	11.23	14.85	8.79
Tangible Book Value	35.02	47.79	144.18	253.26	339.11	158.26
Tangible Book Value Per Share	1.51	2.07	6.24	10.95	14.67	8.62
Land	-	7.47	7.47	7.47	7.47	7.47
Buildings	-	52.28	52.21	52.2	52.15	53
Machinery	-	15.79	16.09	15.38	14.15	13.8
Construction In Progress	-	-	0.35	-	-	0.61

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 12, 2026

Data Sources Report a data error